Rezolute, Inc. (NASDAQ:RZLT) Receives Average Recommendation of “Moderate Buy” from Brokerages

Rezolute, Inc. (NASDAQ:RZLT) has earned an average recommendation of “Moderate Buy” from the eleven ratings firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $8.75.

A number of brokerages have recently issued reports on RZLT. Wall Street Zen raised Rezolute from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Wedbush increased their target price on Rezolute from $5.00 to $6.00 and gave the stock an “outperform” rating in a research note on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Rezolute in a research note on Tuesday, April 21st. Citigroup upgraded Rezolute from a “market perform” rating to an “outperform” rating in a report on Wednesday. Finally, Citizens Jmp upgraded Rezolute from a “market perform” rating to an “outperform” rating and set a $11.00 price target on the stock in a report on Wednesday.

Rezolute Trading Down 1.5%

Shares of RZLT stock opened at $4.51 on Friday. The company has a market cap of $434.27 million, a price-to-earnings ratio of -5.50 and a beta of 0.68. The stock has a 50 day simple moving average of $3.35 and a 200-day simple moving average of $3.89. Rezolute has a 12-month low of $1.07 and a 12-month high of $11.46.

Rezolute (NASDAQ:RZLT) last issued its earnings results on Tuesday, May 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01. On average, equities analysts forecast that Rezolute will post -0.72 earnings per share for the current fiscal year.

Key Rezolute News

Here are the key news stories impacting Rezolute this week:

• Positive Sentiment: Analysts turned more constructive on Rezolute, with Citizens JMP upgrading the stock to Outperform and setting an $11 price target, while Wedbush raised its target to $6. These moves suggest Wall Street sees more upside after the latest clinical data. Rezolute (NASDAQ:RZLT) Upgraded by Citizens Jmp to “Outperform” Rating Rezolute (NASDAQ:RZLT) Price Target Raised to $6.00 at Wedbush
• Positive Sentiment: Rezolute announced four presentations at the Endocrine Society’s ENDO 2026 meeting, including an oral presentation on the Phase 3 sunRIZE study and posters on ersodetug in congenital and tumor-associated hyperinsulinism. The event gives the company another near-term opportunity to highlight its data and broaden clinical credibility. Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
• Neutral Sentiment: Investor coverage has also pointed to strong insider buying and some mixed institutional positioning, which may support confidence in the name but is not as immediate a stock driver as the trial data and analyst upgrades.

Institutional Investors Weigh In On Rezolute

Institutional investors and hedge funds have recently modified their holdings of the company. Mangrove Partners IM LLC grew its holdings in shares of Rezolute by 25.4% in the 3rd quarter. Mangrove Partners IM LLC now owns 2,882,149 shares of the company’s stock worth $27,092,000 after acquiring an additional 584,660 shares during the period. 22NW LP acquired a new stake in shares of Rezolute in the 3rd quarter worth approximately $7,714,000. Caxton Corp grew its holdings in shares of Rezolute by 23.9% in the 3rd quarter. Caxton Corp now owns 1,986,818 shares of the company’s stock worth $18,676,000 after acquiring an additional 382,832 shares during the period. Integral Health Asset Management LLC grew its holdings in shares of Rezolute by 11.1% in the 3rd quarter. Integral Health Asset Management LLC now owns 2,000,000 shares of the company’s stock worth $18,800,000 after acquiring an additional 200,000 shares during the period. Finally, Knott David M Jr acquired a new stake in shares of Rezolute in the 3rd quarter worth approximately $2,585,000. Institutional investors and hedge funds own 82.97% of the company’s stock.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.